Amgen is back in court and this time it s suing FDA. Amgen filed a complaint, posted on FDA Law Blog , on May 25, 2017 after FDA denied the company six months of pediatric exclusivity under the Best Pharmaceuticals for Children Act (BPCA), for its secondary hyperparathyroidism treatment SensiOriginal Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.